Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
El nuevo inhibidor del factor oral XA APXAB es un nuevo tipo de inhibidor de Factor XA oral desarrollado conjuntamente por Bristol-Myers Squibb y Pfizer. Su nombre comercial es Elelto. Es un nuevo tipo de fármaco anticoagulante oral. Al inhibir un factor de coagulación importante XA, APIXAB puede prevenir la generación de trombina y la trombosis.
PRODUCTOS POR GRUPO : Intermedios API > Intermedio para Cas 503612-47-3
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.